AIDX · 20/20 Biolabs, Inc. · Executive Compensation
$0.36
+0.01 (+2.16%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The accompanying condensed financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying condensed financial statements do not include any adjustments relating to the recoverability and classification of assets and their carrying amounts, or the amounts and classification of liabilities that may result should the Company be unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.”View the 10-Q filed Aug 14, 2026
Market Cap
$5.31M
Shares
12.77M
Volume · Oct 5
119.88K
Avg daily vol (3M)
93.15K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jonathan Cohen | Chief Executive Officer | $325,499 |
| Jiming Zhou | Chief Operating Officer | $225,647 |
| Michael Lebowitz | Chief Scientific Officer | $151,600 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jonathan Cohen | Chief Executive Officer | $796,257 |
| Jiming Zhou | Chief Operating Officer | $667,169 |
| Michael Lebowitz | Chief Scientific Officer | $270,353 |